Drug Profile
KOB 03
Alternative Names: KOB-03Latest Information Update: 24 Oct 2018
Price :
$50
*
At a glance
- Originator Dongguk University
- Developer Dong Wha Pharmaceutical; Dongguk University
- Class Anti-inflammatories; Antiallergics; Herbal medicines
- Mechanism of Action Cytokine inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Gene expression inhibitors; Histamine release inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell modulators; NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 24 Oct 2018 No development reported - Phase-II for Allergic rhinitis in South Korea (PO)
- 16 Dec 2015 Phase-II development for Allergic rhinitis is ongoing in South Korea
- 15 Nov 2013 Dongguk University and Dong Wha Pharmaceuticals enter into technology transfer agreement for the development of KOB 03